Phase I Trial of Expanded, Activated Autologous NK-cell Infusions with Trastuzumab in Patients with HER2-positive Cancers.

Soo-Chin LeeNoriko ShimasakiJoline S J LimAndrea WongKritika Yadav Wei Peng YongLip Kun TanLiang Piu KohMichelle L M PoonSing Huang TanSamuel Guan Wei OwLavina BharwaniYoon Sim YapMabel Z Q FooElaine Coustan-SmithRaghav SundarHon Lyn TanWan Qin ChongNesaretnam Barr KumarakulasingheJedidah L M LieowPriscillia J X KoeBoon Cher GohDario Campana

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)

NK-cell therapy in combination with trastuzumab was well tolerated, with target engagement and preliminary antitumor activity, supporting continued assessment of this approach in phase II trials.

Keyphrases

cell therapy
phase ii
nk cells
clinical trial
epidermal growth factor receptor
open label
metastatic breast cancer
phase iii
stem cells
mesenchymal stem cells
placebo controlled
double blind
social media
bone marrow